Abstract:Objectives This study was designed to assess the clinical course and to identify risk factors for life-threatening events in patients with long-QT syndrome (LQTS) with normal corrected QT (QTc) intervals.Background Current data regarding the outcome of patients with concealed LQTS are limited.Methods Clinical and genetic risk factors for aborted cardiac arrest (ACA) or sudden cardiac death (SCD) from birth through age 40 years were examined in 3,386 genotyped subjects from 7 multinational LQTS registries, categorized as LQTS with normal-range QTc (<= 440 ms [n = 469]), LQTS with prolonged QTc interval (>440 ms [ n = 1,392]), and unaffected family members (genotyped negative with <= 440 ms [ n = 1,525]).Results The cumulative probability of ACA or SCD in patients with LQTS with normal-range QTc intervals (4%) was significantly lower than in those with prolonged QTc intervals (15%) (p < 0.001) but higher than in unaffected family members (0.4%) (p < 0.001). Risk factors ACA or SCD in patients with normal-range QTc intervals included mutation characteristics (transmembrane-missense vs. nontransmembrane or nonmissense mutations: hazard ratio: 6.32; p = 0.006) and the LQTS genotypes (LQTS type 1: LQTS type 2, hazard ratio: 9.88; p = 0.03; LQTS type 3: LQTS type 2, hazard ratio: 8.04; p = 0.07), whereas clinical factors, including sex and QTc duration, were associated with a significant increase in the risk for ACA or SCD only in patients with prolonged QTc intervals (female age >13 years, hazard ratio: 1.90; p = 0.002; QTc duration, 8% risk increase per 10-ms increment; p = 0.002).Conclusions Genotype-confirmed patients with concealed LQTS make up about 25% of the at-risk LQTS population. Genetic data, including information regarding mutation characteristics and the LQTS genotype, identify increased risk for ACA or SCD in this overall lower risk LQTS subgroup. (J Am Coll Cardiol 2011;57:51-9) (C) 2011 by the American College of Cardiology Foundation

Po-Ces-01 High-Throughput Screen Identifies Evacetrapib As Candidate Drug To Treat Long Qt Syndrome Type 2

Mutations In Cytoplasmic Loops Of The Kcnq1 Channel And The Risk Of Life-Threatening Events Implications For Mutation-Specific Response To Beta-Blocker Therapy In Type 1 Long-Qt Syndrome

Risk for Life-Threatening Cardiac Events in Patients with Genotype-Confirmed Long-Qt Syndrome and Normal-Range Corrected QT Intervals.

Denaturing High-Performance Liquid Chromatography Quickly And Reliably Detects Cardiac Ion Channel Mutations In Long Qt Syndrome

[Clinical Practice Guidelines for Long Q-T Interval Syndrome].

Clinical Aspects of Type-1 Long-Qt Syndrome by Location, Coding Type, and Biophysical Function of Mutations Involving the KCNQ1 Gene.

Clinical Aspects of Type 3 Long-QT Syndrome: an International Multicenter Study.

PO-630-04 ELUCIDATION OF ALG10B AS A NOVEL LONG QT SYNDROME SUSCEPTIBILITY GENE

PO-646-04 FUNCTIONAL CHARACTERIZATION AND IDENTIFICATION OF A THERAPEUTIC FOR A NOVEL SCN5A-F1760C VARIANT CAUSING TYPE 3 LONG QT SYNDROME REFRACTORY TO ALL GUIDELINE DIRECTED THERAPIES

Mutations in Cytoplasmic Loops of the KCNQ1 Channel and the Risk of Life-Threatening Events

Mutations in conserved amino acids in the KCNQ1 channel and risk of cardiac events in type-1 long-QT syndrome.

From genes to clinical management: A comprehensive review of long QT syndrome pathogenesis and treatment

Identification and characterization of two novel KCNH2 mutations contributing to long QT syndrome

Novel Compound Heterozygous Mutations in the KCNQ1 Gene Associated with Autosomal Recessive Long QT Syndrome (jervell and Lange‐Nielsen Syndrome)

Correction of Defective Protein Trafficking of a Mutant HERG Potassium Channel in Human Long QT Syndrome

Pharmacological activation of the hERG K+ channel for the management of the long QT syndrome: A review

Identifying genomic variant associated with long QT syndrome type 2 in an ecuadorian mestizo individual: a case report

Modeling long QT syndrome type 2 on-a-chip via in-depth assessment of isogenic gene-edited 3D cardiac tissues

Molecular Insights into the Rescue Mechanism of an hERG Activator Against Severe LQT2 Mutations.

Computational insights into the mechanisms underlying structural destabilization and recovery in trafficking-deficient hERG mutants

Architectural T-Wave Analysis and Identification of On-Therapy Breakthrough Arrhythmic Risk in Type 1 and Type 2 Long-QT Syndrome